{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T11:48:54Z","timestamp":1794311334992,"version":"4.9.0"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T00:00:00Z","timestamp":1776124800000},"content-version":"vor","delay-in-days":13,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1038\/s41591-026-04314-9","type":"journal-article","created":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T09:02:02Z","timestamp":1776157322000},"page":"1411-1420","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Antisense oligonucleotide-mediated knockdown therapy in two infants with severe KCNT1 epileptic encephalopathy"],"prefix":"10.1038","volume":"32","author":[{"given":"Tojo","family":"Nakayama","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christelle M.","family":"El Achkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisseth E.","family":"Burbano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2859-7446","authenticated-orcid":false,"given":"Imran H.","family":"Quraishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3479-5561","authenticated-orcid":false,"given":"Jing","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melody","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-5237-5620","authenticated-orcid":false,"given":"Yutaro","family":"Asami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean R.","family":"Golinski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Sherrill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin D.","family":"Goodlett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio M.","family":"de Gusmao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle A.","family":"Friedman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Lentucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Suslovitch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivia","family":"Riccardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamli N. W.","family":"Faour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley","family":"Kuniholm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8633-0032","authenticated-orcid":false,"given":"Aubrie","family":"Soucy Verran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siobhan","family":"Coffman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Banu","family":"Ahtam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2337-5756","authenticated-orcid":false,"given":"Boxun","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1645-3552","authenticated-orcid":false,"given":"Diana H.","family":"Chin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renata L.","family":"DiDonato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunguang A.","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-5316-8869","authenticated-orcid":false,"given":"Edith","family":"Lopez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Hills","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1876-5872","authenticated-orcid":false,"given":"Snezana","family":"Maljevic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helene","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6668-188X","authenticated-orcid":false,"given":"Lynn W.","family":"Bush","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia Ellen","family":"Grant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-5377-8997","authenticated-orcid":false,"given":"Joseph R.","family":"Madsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1937-6529","authenticated-orcid":false,"given":"Richard S.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5128-6326","authenticated-orcid":false,"given":"Leonard K.","family":"Kaczmarek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles B.","family":"Berde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2988-7701","authenticated-orcid":false,"given":"Timothy W.","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,14]]},"reference":[{"key":"4314_CR1","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1002\/ana.25619","volume":"86","author":"R Burgess","year":"2019","unstructured":"Burgess, R. et al. The genetic landscape of epilepsy of infancy with migrating focal seizures. Ann. Neurol. 86, 821\u2013831 (2019).","journal-title":"Ann. Neurol."},{"key":"4314_CR2","doi-asserted-by":"publisher","first-page":"2996","DOI":"10.1093\/brain\/awz240","volume":"142","author":"M Kuchenbuch","year":"2019","unstructured":"Kuchenbuch, M. et al. KCNT1 epilepsy with migrating focal seizures shows a temporal sequence with poor outcome, high mortality and SUDEP. Brain 142, 2996\u20133008 (2019).","journal-title":"Brain"},{"key":"4314_CR3","doi-asserted-by":"publisher","first-page":"D1038","DOI":"10.1093\/nar\/gky1151","volume":"47","author":"JS Amberger","year":"2019","unstructured":"Amberger, J. S., Bocchini, C. A., Scott, A. F. & Hamosh, A. OMIM.org: leveraging knowledge across phenotype\u2013gene relationships. Nucleic Acids Res. 47, D1038\u2013D1043 (2019).","journal-title":"Nucleic Acids Res."},{"key":"4314_CR4","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1038\/ng.2441","volume":"44","author":"G Barcia","year":"2012","unstructured":"Barcia, G. et al. De novo gain-of-function KCNT1 channel mutations cause malignant migrating partial seizures of infancy. Nat. Genet. 44, 1255\u20131259 (2012).","journal-title":"Nat. Genet."},{"key":"4314_CR5","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1111\/epi.16480","volume":"61","author":"F Borlot","year":"2020","unstructured":"Borlot, F. et al. KCNT1-related epilepsy: an international multicenter cohort of 27 pediatric cases. Epilepsia 61, 679\u2013692 (2020).","journal-title":"Epilepsia"},{"key":"4314_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1124\/pr.116.012864","volume":"69","author":"LK Kaczmarek","year":"2017","unstructured":"Kaczmarek, L. K. et al. International Union of Basic and Clinical Pharmacology. C. Nomenclature and properties of calcium-activated and sodium-activated potassium channels. Pharmacol. Rev. 69, 1\u201311 (2017).","journal-title":"Pharmacol. Rev."},{"key":"4314_CR7","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1101\/lm.037820.114","volume":"22","author":"AE Bausch","year":"2015","unstructured":"Bausch, A. E. et al. The sodium-activated potassium channel Slack is required for optimal cognitive flexibility in mice. Learn. Mem. 22, 323\u2013335 (2015).","journal-title":"Learn. Mem."},{"key":"4314_CR8","doi-asserted-by":"publisher","first-page":"7438","DOI":"10.1523\/JNEUROSCI.1628-18.2019","volume":"39","author":"IH Quraishi","year":"2019","unstructured":"Quraishi, I. H. et al. An epilepsy-associated KCNT1 mutation enhances excitability of human iPSC-derived neurons by increasing Slack KNa currents. J. Neurosci. 39, 7438\u20137449 (2019).","journal-title":"J. Neurosci."},{"key":"4314_CR9","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1016\/j.celrep.2014.11.015","volume":"9","author":"GE Kim","year":"2014","unstructured":"Kim, G. E. et al. Human slack potassium channel mutations increase positive cooperativity between individual channels. Cell Rep. 9, 1661\u20131672 (2014).","journal-title":"Cell Rep."},{"key":"4314_CR10","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1002\/ana.24128","volume":"75","author":"CJ Milligan","year":"2014","unstructured":"Milligan, C. J. et al. KCNT1 gain of function in 2 epilepsy phenotypes is reversed by quinidine. Ann. Neurol. 75, 581\u2013590 (2014).","journal-title":"Ann. Neurol."},{"key":"4314_CR11","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1002\/ana.24520","volume":"78","author":"MA Mikati","year":"2015","unstructured":"Mikati, M. A. et al. Quinidine in the treatment of KCNT1-positive epilepsies. Ann. Neurol. 78, 995\u2013999 (2015).","journal-title":"Ann. Neurol."},{"key":"4314_CR12","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","volume":"377","author":"RS Finkel","year":"2017","unstructured":"Finkel, R. S. et al. Nusinersen versus sham control in infantile-onset spinal muscular atrophy. N. Engl. J. Med. 377, 1723\u20131732 (2017).","journal-title":"N. Engl. J. Med."},{"key":"4314_CR13","doi-asserted-by":"crossref","unstructured":"Ziegler, A. et al. Antisense oligonucleotide therapy in an individual with KIF1A-associated neurological disorder. Nat. Med. 30, 2782\u20132786 (2024).","DOI":"10.1038\/s41591-024-03197-y"},{"key":"4314_CR14","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.1056\/NEJMoa1813279","volume":"381","author":"J Kim","year":"2019","unstructured":"Kim, J. et al. Patient-customized oligonucleotide therapy for a rare genetic disease. N. Engl. J. Med. 381, 1644\u20131652 (2019).","journal-title":"N. Engl. J. Med."},{"key":"4314_CR15","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/s41591-021-01615-z","volume":"28","author":"VA Korobeynikov","year":"2022","unstructured":"Korobeynikov, V. A., Lyashchenko, A. K., Blanco-Redondo, B., Jafar-Nejad, P. & Shneider, N. A. Antisense oligonucleotide silencing of FUS expression as a therapeutic approach in amyotrophic lateral sclerosis. Nat. Med. 28, 104\u2013116 (2022).","journal-title":"Nat. Med."},{"key":"4314_CR16","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1038\/s41591-021-01557-6","volume":"28","author":"H Tran","year":"2022","unstructured":"Tran, H. et al. Suppression of mutant C9orf72 expression by a potent mixed backbone antisense oligonucleotide. Nat. Med. 28, 117\u2013124 (2022).","journal-title":"Nat. Med."},{"key":"4314_CR17","doi-asserted-by":"publisher","unstructured":"Burbano, L. E. et al. Antisense oligonucleotide therapy for KCNT1 encephalopathy. JCI Insight https:\/\/doi.org\/10.1172\/jci.insight.146090 (2022).","DOI":"10.1172\/jci.insight.146090"},{"key":"4314_CR18","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1016\/j.cmet.2018.03.004","volume":"27","author":"ST Crooke","year":"2018","unstructured":"Crooke, S. T., Witztum, J. L., Bennett, C. F. & Baker, B. F. RNA-targeted therapeutics. Cell Metab. 27, 714\u2013739 (2018).","journal-title":"Cell Metab."},{"key":"4314_CR19","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1007\/978-1-61779-424-7_25","volume":"815","author":"HS Soifer","year":"2012","unstructured":"Soifer, H. S. et al. Silencing of gene expression by gymnotic delivery of antisense oligonucleotides. Methods Mol. Biol. 815, 333\u2013346 (2012).","journal-title":"Methods Mol. Biol."},{"key":"4314_CR20","doi-asserted-by":"crossref","unstructured":"Korte, S. A.-O. et al. Range of neurological signs in cynomolgus monkeys after intrathecal bolus administration of antisense oligonucleotides. Int. J. Toxicol. 39, 505\u2013509 (2020).","DOI":"10.1177\/1091581820948454"},{"key":"4314_CR21","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.omtn.2022.12.010","volume":"31","author":"C Jia","year":"2023","unstructured":"Jia, C. et al. Change of intracellular calcium level causes acute neurotoxicity by antisense oligonucleotides via CSF route. Mol. Ther. Nucleic Acids 31, 182\u2013196 (2023).","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"4314_CR22","doi-asserted-by":"publisher","first-page":"4401","DOI":"10.1016\/j.ymthe.2024.10.024","volume":"32","author":"MP Moazami","year":"2024","unstructured":"Moazami, M. P. et al. Quantifying and mitigating motor phenotypes induced by antisense oligonucleotides in the central nervous system. Mol. Ther. 32, 4401\u20134417 (2024).","journal-title":"Mol. Ther."},{"key":"4314_CR23","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1089\/nat.2021.0071","volume":"32","author":"PH Hagedorn","year":"2022","unstructured":"Hagedorn, P. H. et al. Acute neurotoxicity of antisense oligonucleotides after intracerebroventricular injection into mouse brain can be predicted from sequence features. Nucleic Acid Ther. 32, 151\u2013162 (2022).","journal-title":"Nucleic Acid Ther."},{"key":"4314_CR24","doi-asserted-by":"publisher","first-page":"664710","DOI":"10.3389\/fneur.2022.664710","volume":"13","author":"L Cornelissen","year":"2022","unstructured":"Cornelissen, L., Donado, C., Yu, T. W. & Berde, C. B. Modified sensory testing in non-verbal patients receiving novel intrathecal therapies for neurological disorders. Front. Neurol. 13, 664710 (2022).","journal-title":"Front. Neurol."},{"key":"4314_CR25","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1002\/acn3.50847","volume":"6","author":"TS Gertler","year":"2019","unstructured":"Gertler, T. S. et al. Functional consequences of a KCNT1 variant associated with status dystonicus and early-onset infantile encephalopathy. Ann. Clin. Transl. Neurol. 6, 1606\u20131615 (2019).","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"4314_CR26","doi-asserted-by":"publisher","first-page":"A4","DOI":"10.1016\/j.ejpn.2023.01.003","volume":"42","author":"J Xian","year":"2023","unstructured":"Xian, J. & Helbig, I. Guardians of the epilepsy genome. Eur. J. Paediatr. Neurol. 42, A4\u2013A6 (2023).","journal-title":"Eur. J. Paediatr. Neurol."},{"key":"4314_CR27","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.yebeh.2014.12.022","volume":"47","author":"CM El Achkar","year":"2015","unstructured":"El Achkar, C. M. & Spence, S. J. Clinical characteristics of children and young adults with co-occurring autism spectrum disorder and epilepsy. Epilepsy Behav. 47, 183\u2013190 (2015).","journal-title":"Epilepsy Behav."},{"key":"4314_CR28","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1038\/s41582-018-0099-3","volume":"14","author":"ST Demarest","year":"2018","unstructured":"Demarest, S. T. & Brooks-Kayal, A. From molecules to medicines: the dawn of targeted therapies for genetic epilepsies. Nat. Rev. Neurol. 14, 735\u2013745 (2018).","journal-title":"Nat. Rev. Neurol."},{"key":"4314_CR29","doi-asserted-by":"publisher","first-page":"1282201","DOI":"10.3389\/fnins.2023.1282201","volume":"17","author":"SF Hill","year":"2023","unstructured":"Hill, S. F., Jafar-Nejad, P., Rigo, F. & Meisler, M. H. Reduction of Kcnt1 is therapeutic in mouse models of SCN1A and SCN8A epilepsy. Front. Neurosci. 17, 1282201 (2023).","journal-title":"Front. Neurosci."},{"key":"4314_CR30","doi-asserted-by":"publisher","first-page":"e55","DOI":"10.1212\/WNL.0000000000004762","volume":"90","author":"A McTague","year":"2018","unstructured":"McTague, A. et al. Clinical and molecular characterization of KCNT1-related severe early-onset epilepsy. Neurology 90, e55\u2013e66 (2018).","journal-title":"Neurology"},{"key":"4314_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-60028-z","volume":"10","author":"IH Quraishi","year":"2020","unstructured":"Quraishi, I. H. et al. Impaired motor skill learning and altered seizure susceptibility in mice with loss or gain of function of the Kcnt1 gene encoding Slack (KNa 1.1) Na+-activated K+ channels. Sci. Rep. 10, 3213 (2020).","journal-title":"Sci. Rep."},{"key":"4314_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1089\/nat.2022.0061","volume":"33","author":"A Goyenvalle","year":"2022","unstructured":"Goyenvalle, A. et al. Considerations in the preclinical assessment of the safety of antisense oligonucleotides. Nucleic Acid Ther. 33, 1\u201316 (2022).","journal-title":"Nucleic Acid Ther."},{"key":"4314_CR33","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1007\/978-981-16-4254-8_18","volume":"1349","author":"Q Zhang","year":"2021","unstructured":"Zhang, Q., Liu, Y., Xu, J., Teng, Y. & Zhang, Z. The functional properties, physiological roles, channelopathy and pharmacological characteristics of the Slack (KCNT1) channel. Adv. Exp. Med. Biol. 1349, 387\u2013400 (2021).","journal-title":"Adv. Exp. Med. Biol."},{"key":"4314_CR34","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1212\/WNL.0000000000008074","volume":"93","author":"J-i Takanashi","year":"2019","unstructured":"Takanashi, J. -i & Takase, N. Reader response: Evidence in focus: Nusinersen use in spinal muscular atrophy: report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology 93, 464 (2019).","journal-title":"Neurology"},{"key":"4314_CR35","unstructured":"Medicines and Healthcare Products Regulatory Agency. Nusinersen (Spinraza\u25bc): reports of communicating hydrocephalus; discuss symptoms with patients and carers and investigate urgently. Drug Safety Update 12, https:\/\/www.gov.uk\/drug-safety-update\/nusinersen-spinraza-reports-of-communicating-hydrocephalus-discuss-symptoms-with-patients-and-carers-and-investigate-urgently (2018)."},{"key":"4314_CR36","doi-asserted-by":"crossref","unstructured":"New warning of nusinersen-related communicating hydrocephalus. Reactions Weekly 1714, 3 (2018).","DOI":"10.1007\/s40278-018-50183-2"},{"key":"4314_CR37","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-021-01822-4","volume":"16","author":"E Viscidi","year":"2021","unstructured":"Viscidi, E. et al. The incidence of hydrocephalus among patients with and without spinal muscular atrophy (SMA): results from a US electronic health records study. Orphanet J. Rare Dis. 16, 207 (2021).","journal-title":"Orphanet J. Rare Dis."},{"key":"4314_CR38","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1056\/NEJMoa1900907","volume":"380","author":"SJ Tabrizi","year":"2019","unstructured":"Tabrizi, S. J. et al. Targeting huntingtin expression in patients with Huntington\u2019s disease. N. Engl. J. Med. 380, 2307\u20132316 (2019).","journal-title":"N. Engl. J. Med."},{"key":"4314_CR39","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1002\/mds.28359","volume":"36","author":"TB Stoker","year":"2021","unstructured":"Stoker, T. B., Andresen, K. E. R. & Barker, R. A. Hydrocephalus complicating intrathecal antisense oligonucleotide therapy for Huntington\u2019s disease. Mov. Disord. 36, 263\u2013264 (2021).","journal-title":"Mov. Disord."},{"key":"4314_CR40","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1002\/ajmg.c.31972","volume":"190","author":"J Wallmeier","year":"2022","unstructured":"Wallmeier, J., Dallmayer, M. & Omran, H. The role of cilia for hydrocephalus formation. Am. J. Med. Genet. C. Semin. Med. Genet. 190, 47\u201356 (2022).","journal-title":"Am. J. Med. Genet. C. Semin. Med. Genet."},{"key":"4314_CR41","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1038\/s41582-020-0321-y","volume":"16","author":"JK Karimy","year":"2020","unstructured":"Karimy, J. K. et al. Inflammation in acquired hydrocephalus: pathogenic mechanisms and therapeutic targets. Nat. Rev. Neurol. 16, 285\u2013296 (2020).","journal-title":"Nat. Rev. Neurol."},{"key":"4314_CR42","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1016\/j.neuron.2013.05.029","volume":"78","author":"Y Zhang","year":"2013","unstructured":"Zhang, Y. et al. Rapid single-step induction of functional neurons from human pluripotent stem cells. Neuron 78, 785\u2013798 (2013).","journal-title":"Neuron"},{"key":"4314_CR43","doi-asserted-by":"publisher","first-page":"113904","DOI":"10.1016\/j.celrep.2024.113904","volume":"43","author":"J Wu","year":"2024","unstructured":"Wu, J., Quraishi, I. H., Zhang, Y., Bromwich, M. & Kaczmarek, L. K. Disease-causing Slack potassium channel mutations produce opposite effects on excitability of excitatory and inhibitory neurons. Cell Rep. 43, 113904 (2024).","journal-title":"Cell Rep."},{"key":"4314_CR44","doi-asserted-by":"publisher","first-page":"2281","DOI":"10.1016\/j.celrep.2016.07.024","volume":"16","author":"MR Fleming","year":"2016","unstructured":"Fleming, M. R. et al. Stimulation of Slack K+ channels alters mass at the plasma membrane by triggering dissociation of a phosphatase-regulatory complex. Cell Rep. 16, 2281\u20132288 (2016).","journal-title":"Cell Rep."},{"key":"4314_CR45","first-page":"25","volume":"47","author":"SE Hess","year":"2008","unstructured":"Hess, S. E. et al. Home improvement: C57BL\/6J mice given more naturalistic nesting materials build better nests. J. Am. Assoc. Lab. Anim. Sci. 47, 25\u201331 (2008).","journal-title":"J. Am. Assoc. Lab. Anim. Sci."},{"key":"4314_CR46","doi-asserted-by":"publisher","first-page":"3558","DOI":"10.1172\/JCI99081","volume":"128","author":"A McCampbell","year":"2018","unstructured":"McCampbell, A. et al. Antisense oligonucleotides extend survival and reverse decrement in muscle response in ALS models. J. Clin. Invest. 128, 3558\u20133567 (2018).","journal-title":"J. Clin. Invest."},{"key":"4314_CR47","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","volume":"29","author":"A Dobin","year":"2013","unstructured":"Dobin, A. et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29, 15\u201321 (2013).","journal-title":"Bioinformatics"},{"key":"4314_CR48","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1093\/bioinformatics\/btt656","volume":"30","author":"Y Liao","year":"2014","unstructured":"Liao, Y., Smyth, G. K. & Shi, W. featureCounts: an efficient general purpose program for assigning sequence reads to genomic features. Bioinformatics 30, 923\u2013930 (2014).","journal-title":"Bioinformatics"},{"key":"4314_CR49","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-014-0550-8","volume":"15","author":"MI Love","year":"2014","unstructured":"Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550 (2014).","journal-title":"Genome Biol."},{"key":"4314_CR50","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","volume":"57","author":"Y Benjamini","year":"1995","unstructured":"Benjamini, Y. & Hochberg, Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J. R. Stat. Soc. Ser. B 57, 289\u2013300 (1995).","journal-title":"J. R. Stat. Soc. Ser. B"},{"key":"4314_CR51","doi-asserted-by":"publisher","first-page":"2084","DOI":"10.1093\/bioinformatics\/bty895","volume":"35","author":"A Zhu","year":"2019","unstructured":"Zhu, A., Ibrahim, J. G. & Love, M. I. Heavy-tailed prior distributions for sequence count data: removing the noise and preserving large differences. Bioinformatics 35, 2084\u20132092 (2019).","journal-title":"Bioinformatics"},{"key":"4314_CR52","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1089\/omi.2011.0118","volume":"16","author":"G Yu","year":"2012","unstructured":"Yu, G., Wang, L. G., Han, Y. & He, Q. Y. clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS 16, 284\u2013287 (2012).","journal-title":"OMICS"},{"key":"4314_CR53","unstructured":"FDA IND Submissions for Individualized Antisense Oligonucleotide Drug Products for Severely Debilitating or Life-Threatening Diseases: Chemistry, Manufacturing, and Controls Recommendations, Guidance for Sponsor-Investigators (FDA, 2021)."},{"key":"4314_CR54","doi-asserted-by":"publisher","DOI":"10.1038\/sdata.2017.112","volume":"4","author":"S Noguchi","year":"2017","unstructured":"Noguchi, S. et al. FANTOM5 CAGE profiles of human and mouse samples. Sci. Data 4, 170112 (2017).","journal-title":"Sci. Data"},{"key":"4314_CR55","unstructured":"Davson, H. & Segal, M. B. Physiology of the CSF and Blood\u2013Brain Barriers (CRC Press, 1996)."},{"key":"4314_CR56","first-page":"73","volume":"79","author":"GP Carlson","year":"2004","unstructured":"Carlson, G. P. & Thiede, M. L. Tissue distribution, excretion, and metabolism of [14C]hydrogen cyanamide in rats. Toxicol. Sci. 79, 73\u201379 (2004).","journal-title":"Toxicol. Sci."},{"key":"4314_CR57","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s12987-015-0001-2","volume":"12","author":"JF Ghersi-Egea","year":"2015","unstructured":"Ghersi-Egea, J. F., Babikian, A., Blondel, S. & Strazielle, N. Changes in the cerebrospinal fluid circulatory system of the developing rat: quantitative volumetric analysis and effect on blood-CSF permeability interpretation. Fluids Barriers CNS 12, 8 (2015).","journal-title":"Fluids Barriers CNS"},{"key":"4314_CR58","doi-asserted-by":"publisher","first-page":"9026","DOI":"10.1093\/nar\/gkab718","volume":"49","author":"BA Anderson","year":"2021","unstructured":"Anderson, B. A. et al. Towards next generation antisense oligonucleotides: mesylphosphoramidate modification improves therapeutic index and duration of effect of gapmer antisense oligonucleotides. Nucleic Acids Res. 49, 9026\u20139041 (2021).","journal-title":"Nucleic Acids Res."},{"key":"4314_CR59","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1038\/s41586-023-06277-0","volume":"619","author":"J Kim","year":"2023","unstructured":"Kim, J. et al. A framework for individualized splice-switching oligonucleotide therapy. Nature 619, 828\u2013836 (2023).","journal-title":"Nature"},{"key":"4314_CR60","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1001\/jamaneurol.2019.1534","volume":"76","author":"C Bridel","year":"2019","unstructured":"Bridel, C. et al. Diagnostic value of cerebrospinal fluid neurofilament light protein in neurology: a systematic review and meta-analysis. JAMA Neurol. 76, 1035\u20131048 (2019).","journal-title":"JAMA Neurol."}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04314-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04314-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04314-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T13:02:05Z","timestamp":1776949325000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04314-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":60,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["4314"],"URL":"https:\/\/doi.org\/10.1038\/s41591-026-04314-9","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"30 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"T.W.Y. has served as an ad hoc scientific consultant to and\/or has received speaker honoraria from Biomarin, GeneTx, Alnylam, SynaptixBio, Third Rock Ventures, Servier Pharmaceuticals and Lilly Pharmaceuticals. He is named as an inventor on three patents pertaining to ASO treatments: for transposon-associated diseases (WO2019055460A1), ataxia telangiectasia (US20230174979A1) and progranulin (US11359199B2). He also serves as a board member of the N=1 Collaborative, the Oligonucleotide Therapeutics Society and the Society for RNA Therapeutics. He is a member of the N=1 Task Force for IRDiRC and also serves as a volunteer advisor to several nonprofit rare disease foundations. H.T. is an employee of R&D Servier Institute Paris-Saclay. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}